Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Renal Pelvis Urothelial Carcinoma

National Cancer Institute (NCI)Small moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Renal Pelvis Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 3BB
MITOMYCIN C
UroGen Pharma Ltd.
Phase 3B
Relatlimab
National Cancer Institute (NCI)
Phase 2/3B

View all 21 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →